Clinical Trials for Neuroprotective Therapies in Intracerebral Hemorrhage: A New Roadmap from Bench to Bedside

Translational Stroke Research

Volumn 3, Issue 4, 2012, Pages 409-417

  Ayer, Amit ^a   Hwang, Brian Y ^a   Appelboom, Geoffrey ^a   Connolly, E Sander ^a  

^a NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Clinical trial; Intracerebral hemorrhage; Neuroprotection

Indexed keywords

CELECOXIB; CITICOLINE; DEFEROXAMINE; DISUFENTON SODIUM; DIZOCILPINE; GAVESTINEL; PIOGLITAZONE; PLACEBO; ROSUVASTATIN; SIMVASTATIN; TAUROURSODEOXYCHOLIC ACID;

BRAIN HEMORRHAGE; BRAIN PROTECTION; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; HEALTH CARE QUALITY; HUMAN; MEDICAL HISTORY; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84869884038     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-012-0207-4     Document Type: Review

References (75)

1. Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet. 2009; 373: 1632-44.
2. Adeoye O, Ringer A, Hornung R, Khatri P, Zuccarello M, Kleindorfer D. Trends in surgical management and mortality of intracerebral hemorrhage in the united states before and after the stich trial. Neurocrit Care. 2010.
3. Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, Karimi A, Shaw MDM, Barer DH, STICH investigators. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the international surgical trial in intracerebral haemorrhage (stich): A randomised trial. Lancet. 2005; 365: 387-97.
4. Mendelow AD, Unterberg A. Surgical treatment of intracerebral haemorrhage. Curr Opin Crit Care. 2007; 13: 169-74.
5. Delcourt C, Huang Y, Wang J, Heeley E, Lindley R, Stapf C, Tzourio C, Arima H, Parsons M, Sun J, Neal B, Chalmers J, Anderson C, Investigators I. The second (main) phase of an open, randomised, multicentre study to investigate the effectiveness of an intensive blood pressure reduction in acute cerebral haemorrhage trial (interact2). Int J Stroke. 2010; 5: 110-6.
6. Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) investigators. Antihypertensive treatment of acute cerebral hemorrhage. Crit Care Med. 2010; 38: 637-48.
7. Qureshi AI. Antihypertensive treatment of acute cerebral hemorrhage (ATACH): rationale and design. Neurocrit Care. 2007; 6: 56-66.
8. Schrot RJ, Muizelaar JP. Mannitol in acute traumatic brain injury. Lancet. 2002; 359: 1633-4.
9. Hwang BY, Appelboom G, Ayer A, Kellner CP, Kotchetkov IS, Gigante PR, Haque R, Kellner M, Connolly ES. Advances in neuroprotective strategies: potential therapies for intracerebral hemorrhage. Cerebrovasc Dis. 2011; 31: 211-22.
10. Xue M, Yong VW. Matrix metalloproteinases in intracerebral hemorrhage. Neurol Res. 2008; 30: 775-82.
11. Lyden P, Wahlgren NG. Mechanisms of action of neuroprotectants in stroke. J Stroke Cerebrovasc Dis. 2000; 9: 9-14.
12. Sacco RL, DeRosa JT, Haley EC Jr, Levin B, Ordronneau P, Phillips SJ, Rundek T, Snipes RG, Thompson JL, Glycine Antagonist in Neuroprotection (GAIN) Americas Investigators. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA. 2001; 285: 1719-28.
13. The North American Glycine Antagonist in Neuroprotection (GAIN) Investigators. Phase II studies of the glycine antagonist gv150526 in acute stroke: the north American experience. The north American glycine antagonist in neuroprotection (gain) investigators. Stroke. 2000; 31: 358-65.
14. Lees KR, Lavelle JF, Cunha L, Diener HC, Sanders EA, Tack P, Wester P, Group GPIES. Glycine antagonist (gv150526) in acute stroke: a multicentre, double-blind placebo-controlled phase II trial. Cerebrovasc Dis. 2001; 11: 20-9.
15. Yam PS, Dunn LT, Graham DI, Dewar D, McCulloch J. NMDA receptor blockade fails to alter axonal injury in focal cerebral ischemia. J Cereb Blood Flow Metab. 2000; 20: 772-9.
16. Lapchak PA, Araujo DM, Song D, Wei J, Purdy R, Zivin JA. Effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1, 3-disulfonate N-oxide (generic nxy-059) on intracerebral hemorrhage in a rabbit large clot embolic stroke model: combination studies with tissue plasminogen activator. Stroke J Cereb Circ. 2002; 33: 1665-70.
17. Lyden PD, Shuaib A, Lees KR, Davalos A, Davis SM, Diener H-C, Grotta JC, Ashwood TJ, Hardemark H-G, Svensson HH, Rodichok L, Wasiewski WW, Ahlberg G, Investigators CT. Safety and tolerability of nxy-059 for acute intracerebral hemorrhage: The chant trial. Stroke. 2007; 38: 2262-9.
18. Iranmanesh F, Vakilian A. Efficiency of citicoline in increasing muscular strength of patients with nontraumatic cerebral hemorrhage: a double-blind randomized clinical trial. J Stroke Cerebrovasc Dis. 2008; 17: 153-5.
19. Clark W, Gunion-Rinker L, Lessov N, Hazel K. Citicoline treatment for experimental intracerebral hemorrhage in mice. Stroke. 1998; 29: 2136-40.
20. Secades JJ, Alvarez-Sabin J, Rubio F, Lozano R, Davalos A, Castillo J. Citicoline in intracerebral haemorrhage: a double-blind, randomized, placebo-controlled, multi-centre pilot study. Cerebrovasc Dis. 2006; 21: 380-5.
21. Gomis M, Ois A, Rodríguez-Campello A, Cuadrado-Godia E, Jiménez-Conde J, Subirana I, Dávalos A, Roquer J. Outcome of intracerebral haemorrhage patients pre-treated with statins. Eur J Neurol. 2010; 17: 443-8.
22. Karki K, Knight RA, Han Y, Yang D, Zhang J, Ledbetter KA, Chopp M, Seyfried DM. Simvastatin and atorvastatin improve neurological outcome after experimental intracerebral hemorrhage. Stroke. 2009; 40: 3384-9.
23. Leker RR, Khoury ST, Rafaeli G, Shwartz R, Eichel R, Tanne D, Investigators N. Prior use of statins improves outcome in patients with intracerebral hemorrhage: prospective data from the national acute stroke israeli surveys (nasis). Stroke. 2009; 40: 2581-4.
24. Naval NS, Abdelhak TA, Urrunaga N, Zeballos P, Mirski MA, Carhuapoma JR. An association of prior statin use with decreased perihematomal edema. Neurocrit Care. 2008; 8: 13-8.
25. Naval NS, Abdelhak TA, Zeballos P, Urrunaga N, Mirski MA, Carhuapoma JR. Prior statin use reduces mortality in intracerebral hemorrhage. Neurocrit Care. 2008; 8: 6-12.
26. Naval NS, Mirski MA, Carhuapoma JR. Impact of statins on validation of ich mortality prediction models. Neurol Res. 2009; 31: 425-9.
27. Seyfried D, Han Y, Lu D, Chen J, Bydon A, Chopp M. Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats. J Neurosurg. 2004; 101: 104-7.
28. Tapia-Perez H, Sanchez-Aguilar M, Torres-Corzo JG, Rodriguez-Leyva I, Gonzalez-Aguirre D, Gordillo-Moscoso A, Chalita-Williams C. Use of statins for the treatment of spontaneous intracerebral hemorrhage: results of a pilot study. Cen Eur Neurosurg. 2009; 70: 15-20.
29. Dowlatshahi D, Demchuk AM, Fang J, Kapral MK, Sharma M, Smith EE. Association of statins and statin discontinuation with poor outcome and survival after intracerebral hemorrhage. Stroke J Cereb Circ. 2012; 43: 1518-23.
30. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. Stroke; a journal of cerebral circulation. Stroke. 2012; 43(8): 2149-56.
31. Selim M, Yeatts S, Goldstein JN, Gomes J, Greenberg S, Morgenstern LB, Schlaug G, Torbey M, Waldman B, Xi G, Palesch Y. Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. Stroke J Cereb Circ. 2011; 42: 3067-74.
32. Vaughan CJ, Murphy MB, Buckley BM. Statins do more than just lower cholesterol. Lancet. 1996; 348: 1079-82.
33. Endres M, Laufs U. Effects of statins on endothelium and signaling mechanisms. Stroke. 2004; 35: 2708-11.
34. Wang J, Doré S. Inflammation after intracerebral hemorrhage. J Cereb Blood Flow Metab. 2007; 27: 894-908.
35. Nakamura T, Keep RF, Hua Y, Hoff JT, Xi G. Oxidative DNA injury after experimental intracerebral hemorrhage. Brain Res. 2005; 1039: 30-6.
36. Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, Begtrup K, Steiner T, Investigators RAFVIHT. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006; 66: 1175-81.
37. Gebel JM, Jauch EC, Brott TG, Khoury J, Sauerbeck L, Salisbury S, Spilker J, Tomsick TA, Duldner J, Broderick JP. Relative edema volume is a predictor of outcome in patients with hyperacute spontaneous intracerebral hemorrhage. Stroke. 2002; 33: 2636-41.
38. Tapia-Pérez H, González-Aguirre D, Sánchez-Aguilar M, Torres-Corzo J, Rodríguez-Leyva I, Gordillo-Moscoso A. Evaluation of changes in the treatment of spontaneous intracerebral haemorrhage in a regional hospital in mexico. Rev Neurol. 2010; 50: 201-6.
39. Park H-K, Lee S-H, Chu K, Roh J-K. Effects of celecoxib on volumes of hematoma and edema in patients with primary intracerebral hemorrhage. J Neurol Sci. 2009; 279: 43-6.
40. Chu K, Jeong S-W, Jung K-H, Han S-Y, Lee S-T, Kim M, Roh J-K. Celecoxib induces functional recovery after intracerebral hemorrhage with reduction of brain edema and perihematomal cell death. J Cereb Blood Flow Metab. 2004; 24: 926-33.
41. Sinn D-I, Lee S-T, Chu K, Jung K-H, Song E-C, Kim J-M, Park D-K, Kim M, Roh J-K. Combined neuroprotective effects of celecoxib and memantine in experimental intracerebral hemorrhage. Neurosci Lett. 2007; 411: 238-42.
42. Nakamura T, Keep RF, Hua Y, Schallert T, Hoff JT, Xi G. Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. Neurosurg Focus. 2003; 15: ECP4.
43. Okauchi M, Hua Y, Keep RF, Morgenstern LB, Xi G. Effects of deferoxamine on intracerebral hemorrhage-induced brain injury in aged rats. Stroke. 2009; 40: 1858-63.
44. Selim M. Deferoxamine mesylate: a new hope for intracerebral hemorrhage: From bench to clinical trials. Stroke. 2009; 40: S90-1.
45. Hua Y, Keep R, Hoff J, Xi G. Brain injury after intracerebral hemorrhage: the role of thrombin and iron. Stroke. 2007; 38: 759.
46. Kase CS. Intracerebral haemorrhage. Baillieres Clin Neurol. 1995; 4: 247-78.
47. Ducruet AF, Zacharia BE, Hickman ZL, Grobelny BT, Yeh ML, Sosunov SA, Connolly Jr ES. The complement cascade as a therapeutic target in intracerebral hemorrhage. Exp Neurol. 2009; 219: 398-403.
48. Xi G, Hua Y, Keep R, Younger J, Hoff J. Systemic complement depletion diminishes perihematomal brain edema in rats. Stroke. 2001; 32: 162.
49. Qing WG, Dong YQ, Ping TQ, Lai LG, Fang LD, Min HW, Xia L, Heng PY. Brain edema after intracerebral hemorrhage in rats: the role of iron overload and aquaporin 4. J Neurosurg. 2009; 110: 462-8.
50. Zaman K, Ryu H, Hall D, O'Donovan K, Lin KI, Miller MP, Marquis JC, Baraban JM, Semenza GL, Ratan RR. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and atf-1/creb and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin. J Neurosci. 1999; 19: 9821-30.
51. Tanji K, Imaizumi T, Matsumiya T, Itaya H, Fujimoto K, Cui X, Toki T, Ito E, Yoshida H, Wakabayashi K, Satoh K. Desferrioxamine, an iron chelator, upregulates cyclooxygenase-2 expression and prostaglandin production in a human macrophage cell line. Biochim Biophys Acta. 2001; 1530: 227-35.
52. Regan RF, Panter SS. Hemoglobin potentiates excitotoxic injury in cortical cell culture. J Neurotrauma. 1996; 13: 223-31.
53. Lee S-R, Kim H-Y, Hong J-S, Baek W-K, Park J-W. PPARgamma agonist pioglitazone reduces matrix metalloproteinase-9 activity and neuronal damage after focal cerebral ischemia. Biochem Biophys Res Commun. 2009; 380: 17-21.
54. Zhao X, Grotta J, Gonzales N, Aronowski J. Hematoma resolution as a therapeutic target: the role of microglia/macrophages. Stroke. 2009; 40: S92-4.
55. Hyong A, Jadhav V, Lee S, Tong W, Rowe J, Zhang JH, Tang J. Rosiglitazone, a PPAR gamma agonist, attenuates inflammation after surgical brain injury in rodents. Brain Res. 2008; 1215: 218-24.
56. Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol. 2006; 5: 53-63.
57. Rodrigues CM, Sola S, Nan Z, Castro RE, Ribeiro PS, Low WC, Steer CJ. Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc Natl Acad Sci U S A. 2003; 100: 6087-92.
58. Albers GW, Goldstein LB, Hess DC, Wechsler LR, Furie KL, Gorelick PB, Hurn P, Liebeskind DS, Nogueira RG, Saver JL. Stroke treatment academic industry roundtable (stair) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. Stroke J Cereb Circ. 2011; 42: 2645-50.
59. Savitz SI, Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the saint trials. Ann Neurol. 2007; 61: 396-402.
60. Baron JC, von Kummer R, del Zoppo GJ. Treatment of acute ischemic stroke. Challenging the concept of a rigid and universal time window. Stroke J Cereb Circ. 1995; 26: 2219-21.
61. Gladstone DJ, Black SE, Hakim AM. Toward wisdom from failure: lessons from neuroprotective stroke trials and new therapeutic directions. Stroke J Cereb Circ. 2002; 33: 2123-36.
62. Wasserman JK, Schlichter LC. Neuron death and inflammation in a rat model of intracerebral hemorrhage: effects of delayed minocycline treatment. Brain Res. 2007; 1136: 208-18.
63. Maletic-Savatic M, Malinow R, Svoboda K. Rapid dendritic morphogenesis in ca1 hippocampal dendrites induced by synaptic activity. Science. 1999; 283: 1923-7.
64. Lee JC, Cho GS, Choi BO, Kim HC, Kim YS, Kim WK. Intracerebral hemorrhage-induced brain injury is aggravated in senescence-accelerated prone mice. Stroke J Cereb Circ. 2006; 37: 216-22.
65. Gong Y, Xi G, Wan S, Gu Y, Keep RF, Hua Y. Effects of aging on complement activation and neutrophil infiltration after intracerebral hemorrhage. Acta Neurochir Suppl. 2008; 105: 67-70.
66. Wasserman JK, Yang H, Schlichter LC. Glial responses, neuron death and lesion resolution after intracerebral hemorrhage in young vs. Aged rats. Eur J Neurosci. 2008; 28: 1316-28.
67. Thiex R, Kuker W, Muller HD, Rohde I, Schroder JM, Gilsbach JM, Rohde V. The long-term effect of recombinant tissue-plasminogen-activator (rt-pa) on edema formation in a large-animal model of intracerebral hemorrhage. Neurol Res. 2003; 25: 254-62.
68. Stys PK. Anoxic and ischemic injury of myelinated axons in cns white matter: from mechanistic concepts to therapeutics. J Cereb Blood Flow Metab. 1998; 18: 2-25.
69. Schabitz WR, Li F, Fisher M. The N-methyl-d-aspartate antagonist CNS 1102 protects cerebral gray and white matter from ischemic injury following temporary focal ischemia in rats. Stroke. 2000; 31: 1709-14.
70. Danton GH, Dietrich WD. The search for neuroprotective strategies in stroke. AJNR Am J Neuroradiol. 2004; 25: 181-94.
71. Gigante PR, Appelboom G, Hwang BY, Haque RM, Yeh ML, Ducruet AF, Kellner CP, Gorski J, Keesecker SE, Connolly Jr ES. Isoflurane preconditioning affords functional neuroprotection in a murine model of intracerebral hemorrhage. Acta Neurochir Suppl. 2011; 111: 141-4.
72. Gidday JM. Pharmacologic preconditioning: translating the promise. Transl Stroke Res. 2010; 1: 19-30.
73. Nakamura T, Kuroda Y, Yamashita S, Zhang X, Miyamoto O, Tamiya T, Nagao S, Xi G, Keep RF, Itano T. Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage. Stroke. 2008; 39: 463-9.
74. Lipton S, Chen HS. Paradigm shift in neuroprotective drug development: clinically tolerated nmda receptor inhibition by memantine. Cell Death Differ. 2004; 11: 18-20.
75. Barrachina M, Dominguez I, Ambrosio S, Secades J, Lozano R, Ferrer I. Neuroprotective effect of citicoline in 6-hydroxydopamine-lesioned rats and in 6-hydroxydopamine-treated sh-sy5y human neuroblastoma cells. J Neurol Sci. 2003; 215: 105-10.